南京科佰生物科技有限公司
主營(yíng)產(chǎn)品: atcc代理,ATCC細(xì)胞系,ATCC細(xì)胞株,ATCC細(xì)胞庫購買 |
聯(lián)系電話
南京科佰生物科技有限公司
主營(yíng)產(chǎn)品: atcc代理,ATCC細(xì)胞系,ATCC細(xì)胞株,ATCC細(xì)胞庫購買 |
聯(lián)系電話
參考價(jià) | 面議 |
更新時(shí)間:2024-12-27 09:47:39瀏覽次數(shù):810
聯(lián)系我們時(shí)請(qǐng)說明是化工儀器網(wǎng)上看到的信息,謝謝!
供貨周期 | 現(xiàn)貨 | 規(guī)格 | T-25 Flask |
---|---|---|---|
貨號(hào) | CBP74002 | 應(yīng)用領(lǐng)域 | 生物產(chǎn)業(yè) |
主要用途 | 僅限科研使用 |
I. Background | |
抗體依賴的細(xì)胞介導(dǎo)的細(xì)胞毒性作用(ADCC,antibody-dependent cell-mediated cytotoxicity )是指抗體的 Fab 段結(jié)合病毒感染的細(xì)胞或腫瘤細(xì)胞的抗原表位,其 Fc 段與殺 傷細(xì)胞(NK 細(xì)胞、巨噬細(xì)胞等)表面的 FcR 結(jié)合,介導(dǎo)殺傷細(xì)胞直接殺傷靶細(xì)胞,它是 抗腫瘤的治療性抗體藥物發(fā)生作用的一種作用重要機(jī)制。 | |
II. Description | |
ADCC Bioassay Effector Cell F variant (Low Affinity)-Fcγ-NFAT Jurkat 報(bào)告基因藥靶模型 很好的模擬了體內(nèi) ADCC 的信號(hào)轉(zhuǎn)導(dǎo)過程,原理見下圖所示。
| |
III. Introduction | |
Host Cell: | Jurkat |
Expressed gene: | NFAT-Luc-CD16(F158) |
Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Synonym(s): | Antibody-dependent cell-mediated cytotoxicity |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Testing: | Negative |
Storage: | Immediately upon receipt, store in liquid nitrogen. |
Application(s): | Functional(Report Gene) Assay |
IV. Description of Host Cell Line | |
Organism: | Homo sapiens, human |
Tissue: | Peripheral blood |
Disease: | Acute T cell leukemia |
Morphology: | Lymphoblast |
Growth Properties: | Suspension |
Ⅴ. Representative Data |
Figure 2. Recombinant ADCC Bioassay Effector Cell F variant (Low Affinity)- Fcγ-NFAT/Jurkat expressing CD16.
Figure 3. Dose response of CD20 Ab in ADCC Bioassay Effector Cell F variant (Low Affinity)-Fcγ-NFAT Jurkat (C11) with Raji.